about
The pathophysiological basis and consequences of feverCritical Role of Intracellular RyR1 Calcium Release Channels in Skeletal Muscle Function and DiseasePharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamicsStatus dystonicus: a practice guideThermogenesis, muscle hyperplasia, and the origin of birdsGene loss, thermogenesis, and the origin of birdsAnesthetic- and heat-induced sudden death in calsequestrin-1-knockout miceCongenital myopathy results from misregulation of a muscle Ca2+ channel by mutant Stac3.Using Informatics to Improve the Care of Patients Susceptible to Malignant Hyperthermia.Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers.Using exome data to identify malignant hyperthermia susceptibility mutations.Systems analysis of biological networks in skeletal muscle function.Inborn errors of energy metabolism associated with myopathies.Ryanodine receptor channelopathies.Ryanodine receptors: structure, expression, molecular details, and function in calcium release.Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediatorsEffect of prior exercise on thermal sensitivity of malignant hyperthermia-susceptible muscleScreening test for malignant hyperthermia in patients with persistent hyperCKemia: a pilot study.Developing effective drills in preparation for a malignant hyperthermia crisis.Case report on clozapine-associated neuroleptic malignant syndrome.Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's diseaseManagement of malignant hyperthermia: diagnosis and treatment.Anesthetic experience using total intra-venous anesthesia for a patient with Wolf-Hirschhorn syndrome -A case report-.Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor.Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference.Malignant hyperthermia: a pharmacogenetic disorder.Evaluation of suspected malignant hyperthermia events during anesthesia.Endoplasmic reticulum Ca(2+) handling in excitable cells in health and diseaseGenetic risk for malignant hyperthermia in non-anesthesia-induced myopathiesSpecial article: Future directions in malignant hyperthermia research and patient careTriadopathies: an emerging class of skeletal muscle diseases.Oxidative stress, mitochondrial damage, and cores in muscle from calsequestrin-1 knockout miceIs there a link between exertional heat stroke and susceptibility to malignant hyperthermia?AICAR prevents heat-induced sudden death in RyR1 mutant mice independent of AMPK activation.Oxidative capacity and fatigability in run-trained malignant hyperthermia-susceptible miceOxidative stress and successful antioxidant treatment in models of RYR1-related myopathyRhabdomyolysis: a genetic perspective.Rare postoperative delayed malignant hyperthermia after off-pump coronary bypass surgery and brief review of literature.Pharmacogenomics: mapping monogenic mutations to direct therapySarcolipin is a novel regulator of muscle metabolism and obesity.
P2860
Q26740509-82DB057F-ACCE-4CD5-AE5C-8E9C70E12016Q26770423-E5340669-C077-4FEA-A0A8-7D87F9A9F0A8Q26781824-D2C47B08-1C51-482C-B78D-B6902534AFF5Q27023458-1C1B189A-725C-4D41-A17D-C77F1C0ADEE1Q28241433-088394EC-7060-4ADA-A786-786B9AED7437Q28288223-F270CA4E-9F93-473D-BAB0-40D9B3EADC89Q28511309-802AB332-1A82-4E2D-8D3A-C6212D991A56Q30008804-453C5DD6-A6AE-40F2-9B9E-599EC1063EE3Q30152154-854F1798-A4C5-472E-A306-72D8BD9D3BFCQ30495545-CFB04B38-F81A-48EA-88DD-754DDF50742BQ30689554-798D8355-7B70-471F-85E4-662BF9C36475Q33828179-F1F11F67-0408-4656-BEBC-94923BBF562CQ33879587-A2AA9B81-D2AD-483D-A0E9-6D007C9E4F37Q33912937-7F636C94-F95C-4B27-BFFF-BA37410395DBQ34024377-FC54F711-E764-4377-97F2-EE5E6CA667A1Q34279284-663D03E0-C2D4-43AE-8FAC-33B898B7662AQ34307851-2A75E18F-FAC7-43C1-97FB-D709AA80FC38Q34327309-071BCE37-A419-4739-B722-80E8030B62A4Q34330534-602962EA-0393-440B-8B36-E9267172A09BQ34347300-3DD82FC1-2E5E-49F9-A387-44D14EEB48C6Q34409630-318AA6CD-1A71-430F-89C9-5FE4E82D60F0Q34421643-857ADF33-206D-42A3-BB1F-B55C6B87AB45Q34629340-9F58DEBF-2903-4377-A6A7-01185DEA13EAQ34752142-15E57528-D922-4670-8C8B-8CC205D5549AQ34770934-FAC32B69-DC0E-47AE-A92D-D72DAF7C5F9EQ34883560-A6ADC167-CC70-4ED5-B5C0-AB50386F6CEBQ34992920-A6F3D98C-DCD3-4E92-86FB-B87F12DCDC84Q35122788-4C37E24B-2612-4845-A755-955E6DEA38E0Q35209452-22689E7C-4006-450E-AD19-31286117E718Q35250678-944F8FA9-988A-4941-94D2-5F18BB0A5E56Q35340211-10785705-2045-4A91-9BD5-D3423A92B8A7Q35727433-F894EBC5-7F2B-485B-9489-72DF621960CCQ35741486-F7D23B77-6654-47A5-9949-76D66A906A9AQ35742842-A616760E-D410-44A0-8DA7-43406D81F7C7Q35854998-A9A62617-6910-45BE-B01A-43C9F5A5B549Q35888648-8B2CD5FE-7543-47F9-AF19-83DAD016434FQ35908344-05A37D41-AAD4-4A01-84B4-3C1FE84E22FEQ35981590-A6C1CBA9-97C0-4DD9-B2BE-03F115FF62CBQ36068380-AA11124A-112E-440A-864A-F90FF5377982Q36385083-040ECA35-0DA2-4709-9625-D19DEA826398
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Malignant hyperthermia
@ast
Malignant hyperthermia
@en
Malignant hyperthermia
@en-gb
Malignant hyperthermia
@nl
type
label
Malignant hyperthermia
@ast
Malignant hyperthermia
@en
Malignant hyperthermia
@en-gb
Malignant hyperthermia
@nl
prefLabel
Malignant hyperthermia
@ast
Malignant hyperthermia
@en
Malignant hyperthermia
@en-gb
Malignant hyperthermia
@nl
P2093
P2860
P3181
P356
P1476
Malignant hyperthermia
@en
P2093
Danielle James
Henry Rosenberg
Kathryn Stowell
Mark Davis
Neil Pollock
P2860
P2888
P3181
P356
10.1186/1750-1172-2-21
P407
P577
2007-01-01T00:00:00Z
P5875
P6179
1052245759